62 results about "Prophylactic treatment" patented technology

The present application relates to novel immunotherapeutic compositions and uses thereof. The present invention relates generally to an immunotherapeutic composition. More specifically, the present invention relates to an immunotherapeutic composition that immunointeracts with T lymphocytes in a subject suffering from peanut allergy or allergy to other tree nuts. Such compositions preferably react immunologically with T cells in a subject suffering from an allergy to an Ara h 1 and / or Ara h 2 allergen. The compositions of the present invention are useful in the therapeutic or prophylactic treatment of conditions characterized by an abnormal, improper or otherwise unwanted immune response to peanut, Ara h1 and / or Ara h2, or a derivative or homolog thereof.

The invention belongs to the field of chemical synthesis, and relates to a GSTO1 inhibitor and application thereof, and application of the compound in medicines for treating or prophylactically treating diseases related to GSTO1, in particular to a compound shown as a formula I, or an isomer thereof, or pharmaceutically acceptable salt thereof and application thereof, and substituent groups in the formula I are as defined in the specification.

Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods.

The present invention provides therapeutic and / or prophylactic treatments against leishmaniasis in non-human mammals in need of such treatment, said treatments comprising administering oleyl phosphocholine to said non-human mammal. The invention also relates to veterinary (pharmaceutical) compositions adapted, suitable and / or intended for use in these treatments.

The present invention provides a method of therapeutic or prophylactic treatment of microvascular brain disease in a subject comprising orally administering to the subject a reduced form of a compound comprising methylthionine (MT) wherein the administration provides the subject with 8 to 200 mg MT per day, optionally divided into two or more doses.

Provided herein are the methods of using an anti-inflammatory agent for prophylactic therapy to prevent or alleviate CRS and / or NE associated with therapeutic interventions, such as the administration of a nucleic acid encoding a CAR.

The application discloses application of an immune checkpoint inhibitor. One of the applications is the application in the preparation of a drug for preventing and treating cancer in a subject. The embodiments of the application show that the application of the immune checkpoint inhibitor to the early cancer stage (high-grade intraepithelial neoplasia stage (HGIN)) of esophageal squamous cell carcinoma can reverse the progression of esophageal squamous cell carcinoma lesions, effectively control the recurrence and metastasis of cancer.

The present invention relates to a DHP-I inhibitor for use in a method for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease. In some embodiments, it relates to a DHP-I inhibitor for use in a method for the prophylactic treatment of neurodegeneration. The present invention also relates to a DHP-I inhibitor for use as neuroprotectant. It further pertains to related methods for the prophylactic and / or therapeutic treatment of a neuroinflammatory disease and the use of a DHP-I inhibitor in the manufacturing of a medicament for use in these methods. The present invention also provides pharmaceutical compositions and delivery systems for use in the methods of the invention, as well as to a pharmaceutical composition or drug delivery systems suitable for administration by a route bypassing the blood brain barrier (BBB) and / or the blood retinal barrier (BRB), preferably selected intrathecal, intracranial, intranasal and / or ocular administration; or suitable for trespassing the BBB and / or the BRB.

Compositions and principles for use before parturition in the prophylactic treatment of hypocalcemia in ruminant animals include compositions having phosphate binders for the prophylactic treatment of parturient hypocalcemia in ruminant animals. These compositions are presented in unit dosage forms, with one or more doses administered daily to the gastrointestinal tract of the ruminant animal, or in wet form. The composition contains one or more phosphate binders and one or more nutrients selected from minerals, vitamins, and amino acids, as well as a composition that includes an inhibitor of the small intestinal Na-phosphate transporter for the prophylactic treatment of parturient hypocalcemia in ruminant animals. Phosphate binders are selected from aluminum, iron, sevelamer, and lanthanum salts, with either inorganic or organic acids, hydrates thereof, or any mixture thereof.

The present invention describes a (first) anti-HSV antibody or antigen-binding fragment thereof that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising a sequence defined in the claims wherein the antibody or antigen-binding fragment has a sequence of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 a low dissociation rate kdis of up to 5.0 x 10 <-5 > s <-1 > and most preferably up to 2.9 x 10 <-5 > s <-1 >. In addition, the present invention also describes a combination of (A) the (first) anti-HSV antibody or antigen-binding fragment thereof; and (B) a second anti-HSV antibody or antigen-binding fragment thereof that recognizes / binds to glycoprotein B (gB) of HSV-1 and / or HSV-2 wherein the antibody comprises complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3, each comprising the sequences defined in the claims wherein the second antibody has a dissociation constant Kd of at most 40 nM, preferably at most 30 nM, more preferably at most 20 nM, even more preferably at most 15 nM, at most 13 nM and at most 10 nM. Furthermore, the present invention also describes a pharmaceutical composition comprising an effective amount of said anti-HSV antibody or antigen-binding fragment thereof, or a combination of said antibodies, and at least one pharmaceutically acceptable excipient. Furthermore, the present invention also describes an anti-HSV antibody or antigen binding fragment thereof or said combination of said antibodies for use in a method of prophylactic or therapeutic treatment of a disorder or disease as defined in the claims. Furthermore, the present invention also describes a bispecific antibody that binds to glycoprotein B (gB) of HSV-1 and / or HSV-2, comprising: (A) a first binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 of the aforementioned first antibody; and (B) a second binding domain comprising: complementarity determining regions VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2, and VLCDR3 of the aforementioned second antibody; wherein the bispecific antibody has a low dissociation rate kdis of at most 5.0 x 10 <-4 > s <-1 >, preferably at most 1.0 x 10 <-4 > s <-1 >, at most 5.0 x 10 <-5 > s <-1 >, most preferably at most 2.9 x 10 <-5 > s <-1 >. Finally, the present invention describes a trispecific antibody comprising a third binding domain in addition to the first binding domain and the second binding domain as described for the bispecific antibody.

The invention relates to antigen-binding polypeptides comprising the CDR1, CDR2 and CDR3 region of a VHH domain of a camelid heavy chain antibody. The polypeptides bind specifically to CD229 and are therefore suitable for the diagnosis as well as for the therapeutic and prophylactic treatment of diseases characterised by increased CD229 expression. Fusion proteins, conjugates and pharmaceutical compositions comprising the antigen-binding polypeptides are also disclosed. In addition, the invention relates to the use of such antigenbinding polypeptides in methods for detecting CD229 or CD229-expressing cells in a biological sample. Methods for purifying and concentrating CD229 or CD229-expressing cells using the antigen-binding polypeptides are also described.

The invention discloses application of a let-7e inhibitor loaded on nano-vesicles derived from bone marrow mesenchymal stem cells in preventive treatment of postmenopausal osteoporosis, and belongs to the technical field of biological medicines. According to the invention, the let-7e inhibitor is designed and synthesized and is'neutralized ', so that the inhibition of the let-7e inhibitor on an osteogenic gene is relieved, the osteogenic function of osteoblasts is promoted, and meanwhile, the nano-vesicles which are derived from mesenchymal cells and have an anti-inflammatory effect are selected as a delivery tool of the let-7e inhibitor to prevent and treat osteoporosis. Experimental results indicate that the mouse bone marrow mesenchymal stem cell-derived nano-vesicle loaded with the let-7e inhibitor has a good preventive treatment effect on mouse osteoporosis after ovariectomy. A stem cell nano-vesicle treatment platform based on mouse bone marrow mesenchymal stem cell-derived nano-vesicles loaded with let-7e inhibitors is expected to be developed into a novel clinical intervention scheme for preventing postmenopausal osteoporosis.

Provided herein include compounds, compositions, kits and methods for preventing and treating psychiatric disorders. The composition and methods described herein can prophylactically treat a subject prior to and / or after a stressor and / or prior to the recurrence of a stressor, thereby preventing or delaying a relapse of depression or depression-like and / or stress-induced behaviors and disorders. The composition can comprise a serotonin 4 receptor (S-HUR) agonist and an N- methyl-D-aspartate (NMDAR) antagonist and a pharmaceutically acceptable salt, analog, derivative or metabolite thereof.

The present invention relates to a composition comprising a transfection agent and an mRNA encoding at least one human endogenous retroviral (HERV) envelope protein or an immunogenic portion thereof, with a mutation in the immunosuppressive domain (ISD) that reduces its immunosuppressive properties. The invention also relates to the use of this composition in the manufacture of medicaments and in therapeutic and prophylactic treatments.

The present invention provides novel methods for treating and preventing colorectal cancer in a subject by administering a composition comprising β-galactosidase, a bacterial culture capable of producing β-galactosidase, such as an S. thermophilus culture, or a fraction of the culture comprising β-galactosidase. A kit useful for such methods is also provided. In addition, the present invention provides a composition for treating or preventing colon cancer.

The present application relates to a kind of protein combination, kit and system for predicting secondary infection of hepatitis B related liver failure patient, including the use of protein combination in the preparation for predicting secondary infection of hepatitis B related liver failure patient, the combination includes lysozyme LYZ, calmodulin 1 CALM1, heparin cofactor II SERPIND1 and cutin DPT.It is directly reflected that the combination is biomarker "inflammation-coagulation imbalance" this core mechanism of liver disease secondary infection, with high specificity, and the combination is not interfered by liver disease background, more can truly reflect the potential reaction state of body to infection under liver disease background, to overcome the problem of "failure" and "false negative" of traditional index ";The combination can significantly change concentration when patient is admitted to hospital early, without clinical infection signs, to provide key time window for early preventive treatment.

The application provides a miniaturized device for lower limb blood flow intervention using neuromuscular electrical stimulation, which comprises a special intervention layer plate, a muscle pump group layer plate and a micro electrical intervention component; an adapter belt is arranged between the special intervention layer plate and the muscle pump group layer plate and is connected with the special intervention layer plate and the muscle pump group layer plate, and the adapter belt is used for annular fixation of the knee joint; the special intervention layer plate and the muscle pump group layer plate both comprise a layer-by-layer attached air pressure layer, a circuit layer and an adhesive layer, the adhesive layer is in contact with the skin surface, the air pressure layer is connected with an air inlet and outlet assembly at an air inlet end, a plurality of conductive modules are arranged in the circuit layer and are electrically connected with the micro electrical intervention component, the air pressure layer is used for extruding the conductive module to tightly contact the skin, and the contact surface of the conductive module and the skin are in contact through the adhesive layer; the device fuses the pneumatic and electrical stimulation in the miniaturized device, so that the lower limb venous dysfunction patient can more conveniently perform preventive treatment and follow-up treatment on the lower leg, and the risk of lower limb venous embolism is reduced.

The present invention provides biomarkers for predicting immune-related myasthenia gravis, myocarditis, and myositis. The key locus HLA-DQB1 * 03: 03 is obtained through HLA typing, and the method has a good prediction value on whether tumor patients subjected to ICI treatment suffer from irMG and / or myositis and myocarditis or not. The invention provides a screening tool which can identify a potential high-risk irAE patient before ICI treatment, and provides inspiration for preventive treatment development of irMG susceptible people.

The invention provides an application of a mycobacterium tuberculosis antigen Rv1471 in preparation of drugs or vaccines for preventing and / or treating diseases caused by mycobacterium infection. In a cell model, the antigen Rv1471 can promote the maturation of phenotypes and functions of macrophages, and also can mediate training immunity. On the basis, a subunit protein vaccine for expressing the antigen Rv1471 is further constructed. In a mouse immune model, the immunogenicity of the subunit protein vaccine expressing the antigen Rv1471 in a mouse which is not immunized by BCG is measured, and the subunit protein vaccine can promote antigen-specific T cell immune response. In a cell model and an acute infection mouse model, the antigen Rv1471 can provide an effective protection effect against mycobacterium tuberculosis infection. Therefore, the antigen Rv1471 and the subunit vaccine thereof are expected to become a novel preventive / therapeutic tuberculosis vaccine.

The invention refers to the field of neurodegenerative diseases including Alzheimer's Disease and a treatment thereof with a Benzoxazepine compound. Benzoxazepine compounds are e.g. known in the treatment of breast cancer and according to the use of the invention are a first therapeutic and prophylactic treatment for neurodegenerative diseases, including Alzheimer's Disease. The invention further relates to test systems for identifying, mapping, elaborating and evaluating said and further therapeutic and prophylactic uses of compounds of interest and / or other pharmaceutical compositions for the treatment of neurodegenerative diseases, including Alzheimer's Disease. (AD)

The invention discloses a cardiovascular complication risk prediction and dialysis method based on multi-dimensional data, which comprises a dialysate blending device, the dialysate blending device adds a potassium chloride solution into dialysate according to the blood potassium level of a patient to regulate and control the potassium ion concentration of the dialysate, and conveys the potassium ion concentration to a dialysis machine; the prediction and dialysis method comprises the following steps: firstly, collecting multi-dimensional data of a patient, and constructing a cardiovascular complication risk prediction model by utilizing big data analysis and machine learning technologies and combining the multi-dimensional data; predicting the possibility of cardiovascular events caused by blood potassium imbalance of the patient in a future period of time in advance; according to a prediction result, adjusting a dialysate potassium ion concentration strategy of the patient before dialysis; in the later treatment stage, the blood potassium level of the current patient is monitored, regulated and controlled, and individualized treatment is conducted according to the current blood potassium concentration. The potassium ion concentration strategy of the dialysate can be adjusted in advance, preventive treatment is implemented, and the treatment gate is moved forward.

The present invention relates to a combination of a first vaccine comprising a non-replicating immunogen of porcine erysipelothrix sp. And a non-replicating immunogen of porcine parvovirus and a second vaccine comprising a non-replicating immunogen of leptospira sp. And the first vaccine and the second vaccine are jointly injected into corium layers of a first injection part and a second injection part of the pig at different points to prophylactically treat the pig so as to resist swine erysipelothrix erysipelas infection, porcine parvovirus infection and leptospirosis infection.

Systems and methods for treatment of neuropathy are provided. In some examples, a method of prophylactic treatment for a disease state in a patient treatment is provided. The treatment can include (a) positioning an electromagnetic field generator adjacent to a cranial nerve; (b) directing an electromagnetic field from the electromagnetic field generator toward the cranial nerve; and repeating the treatment of steps (a) and (b) no less than one treatment per day according to a treatment plan. In some examples, a method of prophylactic treatment for a disease state in a patient treatment is provided. The treatment can include (a) positioning an electromagnetic field generator adjacent to a spinal nerve; (b) directing an electromagnetic field from the electromagnetic field generator toward the spinal nerve; and repeating the treatment of steps (a) and (b) no less than one treatment per day according to a treatment plan.

The present invention relates to compositions which can be used in immunotherapy and especially to compositions which can be used in immunotherapy for mammals suffering from a peanut allergy. The present invention further relates to the use of the present compositions for the treatment of a mammal suffering from an allergy by immunotherapy and the use of the present compositions in a prophylactic treatment for desentizing the immune system of a mammal for an allergen. Specifically, the present invention relates compositions suitable for immunotherapy comprising an allergen, wherein substantially 100% of said allergen in said composition is complexed with aluminum.

The application belongs to the technical field of medicine, and discloses a substituted naphthalene methyl oxadiazole-aniline compound, a preparation method thereof, a pharmaceutical composition taking the compound as an active ingredient, and application of the compound in treatment and / or prevention of infectious diseases caused by a coronavirus. Specifically, the application relates to a compound shown in formula (I) and isomers thereof, or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing the compound, wherein R1, R2, R3, R4, m and n are as described in the specification. The application aims to prepare a new compound with anti-coronavirus activity, which can be used as a potential new drug for the treatment or preventive treatment of infectious diseases caused by a virus, in particular, diseases caused by a coronavirus.

The invention relates to a protein combination, a kit and a system for predicting secondary infection of a patient with hepatitis B related hepatic failure, and comprises application of the protein combination in preparation of a product for predicting secondary infection of the patient with hepatitis B related hepatic failure, and the combination comprises lysozyme LYZ, calmodulin 1 CALM1, heparin cofactor II SERPIND1 and dermatin DPT. The combination is used as a biomarker to directly reflect a core mechanism of inflammation-blood coagulation imbalance of secondary infection of the liver disease, has high specificity, is not interfered by the liver disease background, and can more truly reflect a potential reaction state of an organism to infection under the liver disease background, so that the problems of failure and false negative of a traditional index are solved; the composition can generate obvious concentration change at the early hospital admission stage of a patient when no clinical infection sign exists, and a key time window is provided for early preventive treatment.

The present invention relates to a system for preventive treatment of neurosensory disorders comprising a galvanic vestibular stimulation device (200) connected to an electrode holder (100) having auricular electrodes powered by electrical signals, and a piece of virtual reality equipment (10) generating real-time images of the moving images viewed through a virtual reality headset covering the user's eyes to create an immersive experience, by displaying computer-generated images simulating a 3D environment. The electrode holder (100) comprises two series of two or three electrodes arranged to be able to make contact with the right and left periauricular regions, each of said series comprising at least one upper electrode and at least one lower electrode. The system further comprises a means for synchronising the video stream and the galvanic stimulation (300), which means is connected, on the one hand, to said piece of virtual reality equipment (400) in order to receive directional information and, on the other hand, to said galvanic stimulation device (200) in order to control the generation of stimulation signals depending on said directional information.

The invention provides application of p-hydroxycinnamic acid in preparation of a medicine for preventing and treating noise-induced deafness. The invention has the advantages that the p-hydroxycinnamic acid has the advantages of strong pertinence, high safety, convenience in medication, good patient compliance and the like, not only effectively overcomes the defects of the existing noise-induced hearing loss treatment medicines, but also provides a brand-new preventive treatment thought; important clinical popularization significance and industrial application prospects are realized.

A method of delivering tumor treating electric fields to a patient after tumor remission using predictive data in a preventive therapy, which includes the steps of: reviewing a scan of the body; identifying remissive tumor-filled areas on the scan; determining a spatial relationship between remissive tumor-filled areas and predicted locations of tumors; arranging an array of insulated electrode elements on the body, the array of electrode elements being coupled to an electric field generator, a control device configured to send a signal to the generator causing the generator to deliver tumor-preventative electric fields to the electrode elements; determining at least two subarray firing configurations for the array of electrode elements for targeting the remissive tumor-filled areas, the subarray firing configurations depending at least in part upon the spatial relationship between the two remissive tumor-filled areas; and delivering the tumor-treating fields to the remissive tumor-filled areas using the subarray firing configurations.

The present invention relates to a composition comprising a transfection agent and a human endogenous retrovirus (HERV) envelope protein having a mutation in its immunosuppressive domain (ISD) that reduces its immunosuppressive properties, or mRNA encoding at least the immunogenic portion thereof. The present invention also relates to the manufacture of pharmaceuticals and the use of this composition in therapeutic and prophylactic treatments.